NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...

Neurizon Therapeutics (ASX:NUZ) plans to implement several initiatives to get the clinical hold lifted of its IND application ...

Neurizon Therapeutics has submitted a formal request to the US FDA for advice on pharmacokinetic studies needed to lift hold ... Read More The post Neurizon moves to lift FDA clinical hold on motor ...

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neurizon Therapeutics Limited (NUZ). However, you won't necessarily see their names in the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.

In this episode, Tylah Tully gives the skinny on Neurizon Therapeutics (ASX:NUZ) HEALEY ALS Platform Trial, as the company ...

ByInvesting.com • Dec 18, 2024 Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study Highlights:Positive preclinical results in human in vitro iPSC Motor ...

Neurizon Therapeutics plans to implement several initiatives to get the clinical hold lifted of its IND application for NUZ-001. The company has been in discussion with the US FDA since February ...

Neurizon Therapeutics (ASX: NUZ) announced last month that the regulator had requested additional animal exposure data be provided to assess adequacy of systemic exposure to NUZ-001 during the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...